- Home
- IREN vs ARQT Comparison
IREN vs ARQT Comparison
Compare IREN & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IREN | ARQT |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1B | 3.3B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IREN | ARQT |
|---|---|---|
| Price | $37.55 | $29.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 7 |
| Target Price | ★ $69.20 | $24.83 |
| AVG Volume (30 Days) | ★ 34.4M | 1.8M |
| Earning Date | 02-11-2026 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.99 | N/A |
| Revenue | ★ $688,554,000.00 | $317,929,000.00 |
| Revenue This Year | $137.91 | $85.51 |
| Revenue Next Year | $122.32 | $30.74 |
| P/E Ratio | $19.26 | ★ N/A |
| Revenue Growth | ★ 234.97 | 129.21 |
| 52 Week Low | $5.13 | $11.13 |
| 52 Week High | $76.87 | $31.77 |
Technical Indicators
Market Signals| Indicator | IREN | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 39.91 | 56.00 |
| Support Level | $40.65 | $27.71 |
| Resistance Level | $43.52 | $30.26 |
| Average True Range (ATR) | 3.03 | 1.01 |
| MACD | 0.31 | -0.25 |
| Stochastic Oscillator | 38.32 | 72.01 |
Price Performance
Historical ComparisonAbout IREN Iris Energy Limited
IREN Ltd is engaged in data center business powering the future of Bitcoin, AI and beyond utilizing renewable energy. Bitcoin mining operations generate revenue by earning Bitcoin through a combination of Block rewards and transaction fees from the operation of its Bitcoin miners and exchanging these Bitcoin for fiat currencies such as USD or CAD.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.